Complications of androgen deprivation therapy in prostate cancer

Current Opinion in Urology

Volumn 19, Issue 3, 2009, Pages 322-326

  Schwandt, Anita ^a   Garcia, Jorge A ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Adverse effects; Androgen deprivation therapy; Hormonal therapy; Prostate cancer

Indexed keywords

ALENDRONIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIANDROGEN; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CHOLESTEROL; CLONIDINE; ESTROGEN DERIVATIVE; FLUTAMIDE; FLUVOXAMINE; GABAPENTIN; GONADORELIN DERIVATIVE; INSULIN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; NILUTAMIDE; PAMIDRONIC ACID; PAROXETINE; PLACEBO; PROGESTERONE DERIVATIVE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; TESTOSTERONE; TRIACYLGLYCEROL; VENLAFAXINE; ZOLEDRONIC ACID;

ANDROGEN DEPRIVATION THERAPY; BONE METASTASIS; CASTRATION; CLINICAL TRIAL; DIABETES MELLITUS; FATIGUE; GYNECOMASTIA; HEALTH EDUCATION; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HOT FLUSH; HUMAN; HYPOCALCEMIA; INSULIN RESISTANCE; JAW OSTEONECROSIS; NEPHROTIC SYNDROME; ORCHIECTOMY; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; ERECTILE DYSFUNCTION; LIBIDO; MALE; PROSTATE TUMOR;

ANDROGEN ANTAGONISTS; ERECTILE DYSFUNCTION; GYNECOMASTIA; HUMANS; LIBIDO; MALE; OSTEOPOROSIS; PROSTATIC NEOPLASMS; QUALITY OF LIFE;

EID: 67649678763     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32832a082c     Document Type: Review

References (39)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96.
2. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 2007; 178 (3 Pt 2):S14-S19.
3. Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 7:472-479.
4. D'Amico AV, Manola J, Loffredo M, et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004; 292:821-827.
5. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281:1591-1597.
6. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate-specific cancer mortality following biochemical failure recurrence after radical prostatectomy. JAMA 2005; 294:433-439.
7. Iversen P, Tyrrell CJ, Kaisary AV, et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of follow up. J Urol 2000; 164:1579-1582.
8. Bales GT, Chodak GW. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology 1996; 47 (1A Suppl):38- 43; discussion 48-53.
9. Mottet N, Prayer-Galetti T, Hammerer P, et al. Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer. BJU Int 2006; 98:20-22.
10. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352:154-164.
11. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345:948-955.
12. Israeli RS, Rosenberg SJ, Saltzstein DR, et al. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer 2007; 5:271-277.
13. Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007; 146:416-424.
14. Michaelson MD, Kaufman DS, Lee H, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonistinduced bone loss in men with prostate cancer. J Clin Oncol 2007; 25:1038-1042. The authors demonstrate the potential role of bisphosphonates in preventing bone loss in patients receiving ADT.
15. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormonerefractory prostate cancer. J Natl Cancer Inst 2004; 96:879-882.
16. Ripamonti CI, Maniezzo M, Campa T, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumor patients with bone metastases treated with bisphosphonates. The experience of the national cancer institute of Milan. Ann Oncol 2009; 20:137-145. Describes important dental measures to prevent osteonecrosis of the jaw while receiving treatment with bisphosphonates.
17. Nishiyama T, Kanazawa S, Watanabe R, et al. Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy. Int J Urol 2004; 11:735-741.
18. Loprinzi CL, Goldberg RM, O'Fallon JR, et al. Transdermal clonidine for ameliorating postorchiectomy hot flashes. J Urol 1994; 151:634-636.
19. Loprinzi CL, Khoyratty BS, Dueck A, et al. Gabapentin for hot flashes in men: NCCTG trial N00CB. J Clin Oncol (Meeting Abstracts) 2007; 25 (18 suppl):9005.
20. Naoe M, Ogawa Y, Shichijo T, et al. Pilot evaluation of selective serotonin reuptake inhibitor antidepressants in hot flash patients under androgendeprivation therapy for prostate cancer. Prostate Cancer Prostatic Dis 2006; 9:275-278.
21. Quella SK, Loprinzi CL, Sloan J, et al. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. J Urol 1999; 162:98-102.
22. Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994; 331:347-352.
23. Gerber GS, Zagaja GP, Ray PS, Rukstalis DB. Transdermal estrogen in the treatment of hot flushes in men with prostate cancer. Urology 2000; 55:97-101.
24. Widmark A, Fossa SD, Lundmo P, et al. Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? evaluation of 253 patients in the randomized scandinavian trial SPCG-7/SFUO-3. Urology 2003; 61:145-151.
25. Perdona S, Autorino R, De Placido S, et al. Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomized controlled trial. Lancet Oncol 2005; 6:295-300.
26. Boccardo F, Rubagotti A, Battaglia M, et al. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol 2005; 23:808-815.
27. Shahidi NT. Androgens and erythropoiesis. N Engl J Med 1973; 289:72-80.
28. Strum SB, McDermed JE, ScholzMC, et al. Anemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 1997; 79:933-941.
29. Lee H,McGovern K, Finkelstein JS, et al. Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agaonist treatment for prostate carcinoma. Cancer 2005; 104:1633-1637.
30. Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002; 87:599-603.
31. Smith MR, Lee H, Nathan DM, et al. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006; 91:1305-1308.
32. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24:4448-4456.
33. Saigal CS, Gore JL, Krupski TL, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007; 110:1493-1500. The authors described the impact of ADT in cardiovascular morbidity and mortality.
34. Tsai HK, D'Amico AV, Sadtesky N, et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007; 99:1516-1524. Discussion of the impact of short-term ADT in cardiovascular mortality.
35. Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol 2008; 54:816-823.
36. Roach M 3rd, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008; 26:585-591.
37. Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol 2009; 27:92-99. These findings contradict previous reports suggesting an increased in the risk of metabolic syndrome and cardiovascular events in patients receiving ADT.
38. Joly F, Alibhai SM, Galica J, et al. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer. J Urol 2006; 176 (6 Pt 1):2443-2447.
39. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of the 'androgen deprivation syndrome' in men receiving androgen deprivation for prostate cancer. Arch Intern Med 2006; 166:465-471.